Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Briacell Therapeutics Corp WT (BCTXW)

Briacell Therapeutics Corp WT (BCTXW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,790 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/12/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1600 +118.75%
on 11/14/24
0.4200 -16.67%
on 11/21/24
+0.0503 (+16.78%)
since 10/21/24
3-Month
0.1089 +221.40%
on 09/10/24
0.5000 -30.00%
on 10/01/24
+0.1000 (+40.00%)
since 08/21/24
52-Week
0.1055 +231.75%
on 07/12/24
2.6000 -86.54%
on 01/04/24
-1.4500 (-80.56%)
since 11/20/23

Most Recent Stories

More News
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

BCT.TO : 1.04 (+22.35%)
BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BCT.TO : 1.04 (+22.35%)
BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BCT.TO : 1.04 (+22.35%)
BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BCT.TO : 1.04 (+22.35%)
BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BCT.TO : 1.04 (+22.35%)
BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer

/PRNewswire/ -- USA News Group - Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in...

BCTXW : 0.3500 (unch)
ONC.TO : 1.38 (-1.43%)
BCT.TO : 1.04 (+22.35%)
ONCY : 0.9952 (-0.33%)
CTMX : 0.8751 (+0.57%)
BCTX : 0.7492 (+24.39%)
RLAY : 4.66 (unch)
HOLX : 78.74 (+0.90%)
IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery...

BCTX : 0.7492 (+24.39%)
BCTXW : 0.3500 (unch)
IPA : 0.3695 (-4.25%)
BCT.TO : 1.04 (+22.35%)
BriaCell Secures License for a Promising Novel Anti-Cancer Agent

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BCT.TO : 1.04 (+22.35%)
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s...

BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BCT.TO : 1.04 (+22.35%)
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 0.3500 (unch)
BCTX : 0.7492 (+24.39%)
BCT.TO : 1.04 (+22.35%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar